NorthX Biologics receives CIR accreditation to support R&D collaboration with French biotech and pharmaceutical companies

NorthX Biologics, a leading biopharmaceutical CDMO, has been officially accredited by the French Ministry of Higher Education and Research for the Crédit d’Impôt Recherche (CIR) program for the years 2025-2026.

The Crédit d’Impôt Recherche (CIR) is a French tax incentive designed to support research and development (R&D) activities within the country. This program allows eligible companies to deduct qualified R&D expenses from their corporate taxes under specific conditions, fostering innovation and scientific advancement.

This accreditation reinforces NorthX Biologics’ role as a trusted innovation partner for France’s pharmaceutical and biotech sectors, providing cost-effective access to advanced R&D services in microbial and mammalian systems.

“Receiving CIR accreditation is a testament to our expertise and the high-quality R&D services we provide. The accreditation underscores our reputation as an innovation driver in the development and manufacture of biopharmaceuticals. We remain committed to enabling R&D-driven organizations in achieving their scientific goals” said Janet Hoogstraate, CEO of NorthX Biologics.

About the CIR Research Tax Credit
The research tax credit (Crédit d’Impôt Recherche, CIR) is a central political tool for the benefit of research and innovation. By promoting R&D, this tax relief can increase the competitiveness of companies. It is adapted to the needs of small and midsize enterprises, in particular. Crédit d’impôt recherche (CIR) | Entreprendre.Service-Public.fr

Read the French version here.